News|Articles|December 31, 2025

Top 5 GLP-1 news articles of 2025

Listen

0:00 / 0:00

Key Takeaways

Long-term adherence to GLP-1 obesity drugs is low, but 2024 data shows improvement, indicating evolving treatment understanding.
Payers are exploring policy options to address the cost-effectiveness and affordability of GLP-1 obesity medications.
Teva's launch of Liraglutide marks the introduction of the first generic GLP-1 drug for obesity treatment.
The FDA's potential approval of oral Wegovy could make it the first oral GLP-1 drug for obesity.
CVS Caremark will designate Wegovy as a preferred GLP-1 option on its formularies starting July 2025.

GLP-1 obesity drugs saw shifting coverage and access in 2025, with low long-term adherence, payer cost concerns, new generics and key regulatory and formulary moves shaping use.

1. Prime study finds low long-term adherence to GLP-1 obesity drugs

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in adherence in 2024, suggesting there is an evolving understanding of obesity treatment.

2. Payers consider policy options for access to GLP-1 obesity medications

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

3. Teva launches first generic GLP-1 drug for obesity

Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight.

4. FDA sets action date for oral Wegovy for weight loss

If approved, Wegovy would be the first oral GLP-1 drug to treat obesity.

5. CVS Caremark to place Wegovy as preferred GLP-1 for weight loss

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.